Literature DB >> 1918470

The pharmacology of methotrexate.

E A Olsen1.   

Abstract

Methotrexate is a useful antimetabolite for the treatment of both benign and malignant proliferative disorders. When the pharmacokinetics and potential toxicity of this drug are understood, treatment regimens can be tailored to the underlying kinetics of the target population. With the appropriate knowledge of the importance of urinary excretion of methotrexate and factors that influence this and with the ready availability of leucovorin, toxicity can be avoided in all but the most unusual of circumstances.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918470     DOI: 10.1016/0190-9622(91)70199-c

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  24 in total

Review 1.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

Authors:  F Bressolle; C Bologna; L Edno; J C Bernard; R Gomeni; J Sany; B Combe
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Targeting the de novo biosynthesis of thymidylate for the development of a PET probe for pancreatic cancer imaging.

Authors:  Thushani D Nilaweera; Muhammad Saeed; Amnon Kohen
Journal:  Biochemistry       Date:  2015-01-27       Impact factor: 3.162

Review 4.  Methotrexate and Pralatrexate.

Authors:  Gary S Wood; Jianqiang Wu
Journal:  Dermatol Clin       Date:  2015-08-01       Impact factor: 3.478

Review 5.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

7.  Decreasing Cost and Decreasing Length of Stay After Implementation of Updated High-Dose Methotrexate Discharge Criteria.

Authors:  Adam F Binder; Samantha Burdette; Patricia Galanis; Katlin Birchmeier; Nathan Handley; Maria Piddoubny
Journal:  JCO Oncol Pract       Date:  2020-02-25

8.  Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

Authors:  Bo Song; Yuan Wang; Matthew A Titmus; Galina Botchkina; Andrea Formentini; Marko Kornmann; Jingfang Ju
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

9.  Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate.

Authors:  G Valesini; R Priori; A Francia; G Balestrieri; A Tincani; P Airo; R Cattaneo; A Zambruni; B Troianello; M Chofflon
Journal:  Springer Semin Immunopathol       Date:  1994

10.  Practical issues with high dose methotrexate therapy.

Authors:  Osama M Al-Quteimat; Mariam A Al-Badaineh
Journal:  Saudi Pharm J       Date:  2014-04-13       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.